Swiss Midcaps Offer Growth Potential Amid Novartis Downturn

Swiss mid-cap stocks have emerged as attractive alternatives to the broader market following Novartis’ 11 percent drop on Tuesday, which dragged down the Swiss Market Index (SMI) by 1.6 percent. The pharmaceutical giant’s underperformance—driven by research setbacks—highlighted the market’s heavy reliance on a handful of heavyweights, including Novartis and Roche, which together account for roughly one-third of the SMI’s weight. Even Nestlé’s 2.1 percent gain failed to offset the broader market’s weakness, underscoring investor concerns about overconcentration in pharmaceuticals.